Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study
- PMID: 15955857
- DOI: 10.1148/radiol.2361040338
Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study
Abstract
Purpose: To prospectively determine the accuracy of differentiating benign focal nodular hyperplasia (FNH) from hepatic adenoma (HA) and liver adenomatosis (LA) by using gadobenate dimeglumine-enhanced magnetic resonance (MR) imaging.
Materials and methods: The ethics committee at each center approved the study, and all patients provided informed consent. Seventy-three patients with confirmed FNH and 35 patients with confirmed HA (n = 27) or LA (n = 8) underwent MR imaging before (T2-weighted half-Fourier rapid acquisition with relaxation enhancement or T2-weighted fast spin-echo and T1-weighted gradient-echo [GRE] sequences) and at 25-30 seconds (arterial phase), 70-90 seconds (portal venous phase), 3-5 minutes (equilibrium phase), and 1-3 hours (delayed phase) after (T1-weighted GRE sequences only, with or without fat suppression) bolus administration of 0.1 mmol per kilogram of body weight gadobenate dimeglumine. The enhancement of 235 lesions (128 FNH, 32 HA, and 75 LA lesions) relative to the normal liver parenchyma was assessed. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy for the differentiation of FNH from HA and LA were determined.
Results: Hyper- and isointensity on T2-weighted and iso- and hypointensity on T1-weighted GRE images were noted for 177 (88.9%) of 199 lesions visible on unenhanced images. On dynamic phase images after contrast material administration, 231 (98.3%) of 235 lesions showed rapid strong enhancement during the arterial phase and appeared hyper- to isointense during portal venous and equilibrium phases. Accurate differentiation of FNH from HA and LA was not possible on the basis of precontrast or dynamic phase images alone. At 1-3 hours after contrast material enhancement, 124 (96.9%) of 128 FNHs appeared hyper- or isointense, while 107 (100%) HA and LA lesions appeared hypointense. The sensitivity, specificity, PPV, NPV, and overall accuracy for the differentiation of FNH from HA and LA were 96.9%, 100%, 100%, 96.4%, and 98.3%, respectively.
Conclusion: Accurate differentiation of FNH from HA and LA is achievable on delayed T1-weighted GRE images after administration of gadobenate dimeglumine.
Copyright RSNA, 2005
Similar articles
-
Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine.Radiology. 2001 Dec;221(3):731-9. doi: 10.1148/radiol.2213010139. Radiology. 2001. PMID: 11719669
-
Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.J Magn Reson Imaging. 2013 Apr;37(4):903-8. doi: 10.1002/jmri.23874. Epub 2012 Oct 12. J Magn Reson Imaging. 2013. PMID: 23065959
-
Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging.J Magn Reson Imaging. 2007 Apr;25(4):775-82. doi: 10.1002/jmri.20885. J Magn Reson Imaging. 2007. PMID: 17348002
-
Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis.Radiographics. 2004 Jan-Feb;24(1):3-17; discussion 18-9. doi: 10.1148/rg.241035050. Radiographics. 2004. PMID: 14730031 Review.
-
Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy.Korean J Radiol. 2009 May-Jun;10(3):294-302. doi: 10.3348/kjr.2009.10.3.294. Epub 2009 Apr 22. Korean J Radiol. 2009. PMID: 19412518 Free PMC article. Review.
Cited by
-
MRI of Focal Liver Lesions.Curr Med Imaging Rev. 2012 May;8(2):107-116. doi: 10.2174/157340512800672216. Curr Med Imaging Rev. 2012. PMID: 23049491 Free PMC article.
-
Texture analysis on routine MRI sequences to differentiate between focal nodular hyperplasia and hepatocellular adenoma.Pol J Radiol. 2023 Dec 21;88:e589-e596. doi: 10.5114/pjr.2023.134043. eCollection 2023. Pol J Radiol. 2023. PMID: 38362015 Free PMC article.
-
Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions.Radiol Med. 2015 Dec;120(12):1100-11. doi: 10.1007/s11547-015-0548-7. Epub 2015 Jun 19. Radiol Med. 2015. PMID: 26088468 Free PMC article.
-
Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT.Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):436-40. doi: 10.1007/s00259-010-1584-0. Epub 2010 Aug 18. Eur J Nucl Med Mol Imaging. 2011. PMID: 20717825 Free PMC article. Clinical Trial.
-
Pedunculated Focal Nodular Hyperplasia: When in Doubt, Should We Cut It Out?J Clin Med. 2023 Sep 18;12(18):6034. doi: 10.3390/jcm12186034. J Clin Med. 2023. PMID: 37762973 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical